Rocco Serrao

Jun 6, 2024 | dermatologytimes.com | Rocco Serrao

June 6, 2024Rocco Serrao, MD, FAAD, addresses potential barriers to access and affordability of narrowband UVB phototherapy and topical medications for vitiligo treatment, while highlighting available resources to assist patients in overcoming these obstacles. How long would you treat this patient with this topical combination?

Jun 6, 2024 | dermatologytimes.com | Rocco Serrao

June 6, 2024Rocco Serrao, MD, FAAD, discusses a case of a 38-year-old male with progressive vitiligo, exploring potential triggers and exacerbating factors, as well as lifestyle changes and treatment options to manage symptoms and improve quality of life. What is your impression of this case? What challenges does this case present with, if any? Can you discuss any potential triggers or exacerbating factors that may have contributed to the onset and progression of vitiligo in this patient?

Jun 6, 2024 | dermatologytimes.com | Rocco Serrao

June 6, 2024Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials. What guidance do you provide to patients with vitiligo upon achieving remission with ruxolitinib treatment? How do you counsel them regarding ongoing management?

Jun 6, 2024 | dermatologytimes.com | Rocco Serrao

June 6, 2024Rocco Serrao, MD, FAAD, a board-certified dermatologist, discusses a case of vitiligo involving a 20-year-old male patient who presents with white patches on his face that have persisted for 6 weeks without any relevant chemical exposures, and emphasizes the importance of providing counseling and support to address the potential impact on the patient's self-esteem and confidence. What is your impression of this case? What challenges does this case present with, if any?

Sep 29, 2023 | dermatologytimes.com | Lauren Buchanan |Rocco Serrao

Rocco Serrao, MD, is a board-certified dermatologist practicing with DOCS Dermatology in Cincinnati and Dayton, Ohio. His passion is in inflammation, especially psoriasis solutions. During his presentation at Maui Derm NP+PA Fall 2023 in Asheville, North Carolina, he looked at current data surrounding bimekizumab.1Bimekizumab will be able to block signaling through the IL-17A/IL-17A, IL-17A/IL-17F, IL-17F/IL17F heterodimers and homodimers.